Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

Estrid V Høgdall; Susanne K Kjaer; Eva Glud; Lise Christensen; Jan Blaakaer; Jens Vuust; Johannes E Bock; Bent Norgaard-Pedersen; Claus K Hogdall

Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

Estrid V Høgdall, Susanne K Kjaer, Eva Glud, Lise Christensen, Jan Blaakaer, Jens Vuust, Johannes E Bock, Bent Norgaard-Pedersen, Claus K Hogdall

12 Citations (Scopus)

Abstract

BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours.

MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing.

RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age.

CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.

Original language	English
Journal	Anticancer Research
Volume	23
Issue number	4
Pages (from-to)	3397-404
Number of pages	8
ISSN	0250-7005
Publication status	Published - 2003
Externally published	Yes

Keywords

Adult
Aged
CA-125 Antigen/blood
Contraceptives, Oral/pharmacology
Female
Genes, p53/genetics
Genotype
Gravidity
Humans
Introns/genetics
Lectins, C-Type/blood
Middle Aged
Neoplasm Staging
Ovarian Neoplasms/blood
Polymorphism, Single-Stranded Conformational
Prognosis
Smoking/genetics

Cite this

@article{1190b22a76764fc089ff889b9cbd0412,

title = "Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish {"}Malova{"} Ovarian Cancer Study",

abstract = "BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours.MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing.RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age.CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.",

keywords = "Adult, Aged, CA-125 Antigen/blood, Contraceptives, Oral/pharmacology, Female, Genes, p53/genetics, Genotype, Gravidity, Humans, Introns/genetics, Lectins, C-Type/blood, Middle Aged, Neoplasm Staging, Ovarian Neoplasms/blood, Polymorphism, Single-Stranded Conformational, Prognosis, Smoking/genetics",

author = "H{\o}gdall, \{Estrid V\} and Kjaer, \{Susanne K\} and Eva Glud and Lise Christensen and Jan Blaakaer and Jens Vuust and Bock, \{Johannes E\} and Bent Norgaard-Pedersen and Hogdall, \{Claus K\}",

year = "2003",

language = "English",

volume = "23",

pages = "3397--404",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

AU - Høgdall, Estrid V

AU - Kjaer, Susanne K

AU - Glud, Eva

AU - Christensen, Lise

AU - Blaakaer, Jan

AU - Vuust, Jens

AU - Bock, Johannes E

AU - Norgaard-Pedersen, Bent

AU - Hogdall, Claus K

PY - 2003

Y1 - 2003

N2 - BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours.MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing.RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age.CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.

AB - BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours.MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing.RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age.CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.

KW - Adult

KW - Aged

KW - CA-125 Antigen/blood

KW - Contraceptives, Oral/pharmacology

KW - Female

KW - Genes, p53/genetics

KW - Genotype

KW - Gravidity

KW - Humans

KW - Introns/genetics

KW - Lectins, C-Type/blood

KW - Middle Aged

KW - Neoplasm Staging

KW - Ovarian Neoplasms/blood

KW - Polymorphism, Single-Stranded Conformational

KW - Prognosis

KW - Smoking/genetics

UR - https://www.scopus.com/pages/publications/0043029872

M3 - Journal article

C2 - 12926080

SN - 0250-7005

VL - 23

SP - 3397

EP - 3404

JO - Anticancer Research

JF - Anticancer Research

IS - 4

ER -

Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study

Abstract

Keywords

Other files and links

Fingerprint

Cite this